{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:07:40Z","timestamp":1765004860607},"reference-count":19,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.ejim.2012.03.017","type":"journal-article","created":{"date-parts":[[2012,5,3]],"date-time":"2012-05-03T03:09:43Z","timestamp":1336014583000},"page":"461-464","source":"Crossref","is-referenced-by-count":12,"title":["Effectiveness of varenicline for smoking cessation at 2 urban academic health centers"],"prefix":"10.1016","volume":"23","author":[{"given":"Ranjit K.","family":"Dhelaria","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Friderici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ella","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cyrus","family":"Khan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael B.","family":"Rothberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejim.2012.03.017_bb0005","first-page":"1226","article-title":"Smoking-attributable mortality, years of potential life lost, and productivity losses\u2014United States, 2000\u20132004","volume":"57","author":"Centers for Disease Control and Prevention","year":"2008","journal-title":"Morb Mortal Wkly Rep"},{"key":"10.1016\/j.ejim.2012.03.017_bb0010","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1360-0443.2004.00540.x","article-title":"Shape of the relapse curve and long-term abstinence among untreated smokers","volume":"99","author":"Hughes","year":"2004","journal-title":"Addiction"},{"key":"10.1016\/j.ejim.2012.03.017_bb0015","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1001\/jama.296.1.56","article-title":"Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial","volume":"296","author":"Jorenby","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.ejim.2012.03.017_bb0020","article-title":"Delayed quitting, lapse recovery and long-term outcomes for quitters taking varenicline, bupropion and placebo","author":"Gonzales","year":"2008"},{"key":"10.1016\/j.ejim.2012.03.017_bb0025","doi-asserted-by":"crossref","first-page":"664","DOI":"10.5993\/AJHB.32.6.10","article-title":"Varenicline versus bupropion SR or placebo for smoking cessation: a pooled analysis","volume":"32","author":"Nides","year":"2008","journal-title":"Am J Health Behav"},{"key":"10.1016\/j.ejim.2012.03.017_bb0030","doi-asserted-by":"crossref","first-page":"2165","DOI":"10.1185\/03007995.2010.505130","article-title":"Varenicline treatment for smoking cessation in Asian populations: a pooled analysis of placebo-controlled trials conducted in six Asian countries","volume":"26","author":"Fagerstr\u00f6m","year":"2010","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2012.03.017_bb0035","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1185\/03007990802177523","article-title":"The efficacy and safety of varenicline for smoking cessation using a flexible dosing strategy in adult smokers: a randomized controlled trial","volume":"24","author":"Niaura","year":"2008","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.ejim.2012.03.017_bb0040","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1136\/thx.2007.090647","article-title":"Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised, open-label trial","volume":"63","author":"Aubin","year":"2008","journal-title":"Thorax"},{"key":"10.1016\/j.ejim.2012.03.017_bb0045","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1253\/circj.CJ-09-0803","article-title":"A randomized controlled open comparative trial of varenicline vs nicotine patch in adult smokers","volume":"74","author":"Tsukahara","year":"2010","journal-title":"Circ J"},{"key":"10.1016\/j.ejim.2012.03.017_bb0050","first-page":"CD006103","article-title":"Nicotine receptor partial agonists for smoking cessation","author":"Cahill","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2012.03.017_bb0055","first-page":"169","article-title":"Foundations of clinical research. Applications to practice","author":"Portney","year":"2009"},{"key":"10.1016\/j.ejim.2012.03.017_bb0060","first-page":"455","article-title":"Practical biostatistical methods","author":"Selvin","year":"1995"},{"key":"10.1016\/j.ejim.2012.03.017_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199903043400903","article-title":"A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation","volume":"340","author":"Jorenby","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejim.2012.03.017_bb0070","series-title":"Treating tobacco use and dependence: clinical practice guideline","author":"Fiore","year":"2000"},{"key":"10.1016\/j.ejim.2012.03.017_bb0075","author":"Massachusetts Tobacco Cessation and Prevention Program"},{"key":"10.1016\/j.ejim.2012.03.017_bb0080","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1111\/j.1365-2753.2010.01439.x","article-title":"A review of cost-effectiveness of varenicline and comparison of cost-effectiveness of treatments for major smoking-related morbidities","volume":"17","author":"Zimovetz","year":"2011","journal-title":"J Eval Clin Pract"},{"key":"10.1016\/j.ejim.2012.03.017_bb0085","first-page":"CD000146","article-title":"Nicotine replacement therapy for smoking cessation","volume":"23","author":"Stead","year":"2008","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ejim.2012.03.017_bb0090","doi-asserted-by":"crossref","first-page":"2033","DOI":"10.1001\/archinte.159.17.2033","article-title":"Randomized comparative trial of nicotine polacrilex, a transdermal patch, nasal spray, and an inhaler","volume":"159","author":"Hajek","year":"1999","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ejim.2012.03.017_bb0095","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.clinthera.2009.03.021","article-title":"Varenicline: a first-line treatment option for smoking cessation","volume":"31","author":"Garrison","year":"2009","journal-title":"Clin Ther"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512000866?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620512000866?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,11,23]],"date-time":"2018-11-23T18:23:57Z","timestamp":1542997437000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620512000866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0953620512000866"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2012.03.017","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}